



BENIGN PROSTATIC HYPERPLASIA

RMA ID Number	Reference List for RMA051-2 as at February 2016
---------------	---

76207	Abrams P (1994). New words for old: lower urinary tract symptoms for "prostatism". <i>BMJ</i> , 308: 929-30.
46911	Agency for Toxic Substances and Disease Registry (2007). Toxicological Profile for Lead, . US Department of Health & Human Services, Public Health Service.
40509	Ambrosini GL, de Klerk NH, Mackerras D, et al (2008). Dietary patterns and surgically treated benign prostatic hyperplasia: a case control study in Western Australia. <i>BJU Int</i> , 101(7): 853-60.
15397	Araki H, Watanabe H, Mishina T, et al (1983). High-risk group for benign prostatic hypertrophy. <i>The Prostate</i> , 4(3): 253-64.
3273	Armenian HK, Lilienfeld AM, Diamond EL, Bross IDJ (1975). Epidemiologic characteristics of patients with prostatic neoplasms. <i>Am J Epidemiol</i> , 102(1): 47-54.
76174	Aune D, Rosenblatt D, Chan D, et al (2015). Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. <i>Am J Clin Nutr</i> , 101(1): 87-117.
76213	Barnard R, Aronson W (2009). Benign prostatic hyperplasia: does lifestyle play a role? <i>Phys Sportsmed</i> , 37(4): 141-6.
46855	Barry MJ (2004). Nephrology: XIII Benign prostatic hyperplasia. <i>ACP Medicine</i> , : 1-9.
76211	Bechis S, Otsetov A, Ge R, et al (2015). Age and obesity promote methylation and suppression of 5a-reductase 2: implications for personalized therapy of benign prostatic hyperplasia. <i>The Journal of Urology</i> , 94: 1031-7.
44917	Berger AP, Bartsch G, Deibl M, Alber H, et al (2006). Atherosclerosis as a risk factor for benign prostatic hyperplasia. <i>BJU International</i> , Vol 98 pp 1038-1042.
45019	Berger AP, Deibl M, Halpern EJ, et al (2005). Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. <i>Diabetologia</i> , 48: 784-9.
45224	Berger RE (2005). Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. <i>J Urology</i> , 174(2) pp 589.
76173	Bernichtein S, Pigat N, Capiod T, et al (2015). High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions. <i>PLoS One</i> , 10(5): e0125423.
46863	Bloomgarden ZT (2006). Aspects of type 2 diabetes and related insulin-resistant states. <i>Diabetes Care</i> , 29(3) pp 732-740.
45078	Boon TA, van Venrooij GEP, Eckhardt MD (2001). Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. <i>Curr Urol Reports</i> , 2(4) pp 297-301.

11200	Bosch JL, Hop WJ, Schroder FH (1995). Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. <i>Urology</i> , 46(Suppl 3A): 34-40.
11428	Bosch R JLH (1991). Pathogenesis of benign prostatic hyperplasia. <i>European Urology</i> , 20(suppl 2): 27-30.
7012	Bourke JB, Griffin JP (1968). Diabetes Mellitus in patients with benign prostatic hyperplasia. <i>BMJ</i> , 4: 492-3.
45194	Boyle P, Liu G, Jacobson S, Ogawa O, et al (2001). Epidemiology and natural history. Benign prostatic hyperplasia. Eds. Health Publication Ltd. Plymbridge Distributors, Ltd, Plymouth, United Kingdom, pp 19-68.
76153	Bravi F, Bosetti C, del Maso L, et al (2006). Food groups and risk of benign prostatic hyperplasia. <i>Urology</i> , 73-9, 67(1): .
45023	Bravi F, Bosetti C, Dal Maso L, Talamini R, et al (2006). Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. <i>Urology</i> , 67(6) pp 1205-11.
45031	Bravi F, Bosetti C, Dal Maso L, Talamini R, et al (2006). Food groups and risk of benign prostatic hyperplasia. <i>Urology</i> , 67(1) pp 73-79.
76212	Breyer B, Huang W, Rabkin C, et al (2015). Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the prostate, lung, colorectal and ovarian cancer screening trial. <i>BJU Int</i> , : doi:10.1111/bju.13050.
45082	Burke JP, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, Lieber MM, Jacobsen SJ (2006). Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota. <i>Urology</i> , 67(1) pp 22-25.
45027	Burke JP, Rhodes T, Jacobson DJ, McGree ME, et al (2006). Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. <i>American Journal of Epidemiology</i> , 164(1) pp 41-46.
44913	Campbell B (2005). High rate of prostate symptoms among arialal men from northern Kenya. <i>The Prostate</i> , Vol 62 pp 83-90.
77005	Cetinkaya M, Cetinkaya H, Ulusoy E, et al (1998). Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia. <i>The Prostate</i> , 36(2): 80-4.
76286	Chen I, Tsal Y, Tong Y (2012). Correlations among cardiovascular risk factors, prostate blood flow, and prostate volume in patients with clinical benign prostatic hyperplasia. <i>Urology</i> , 79: 409-14.
76192	Chiu Y, Kao S, Lin H, et al (2015). Benign prostatic enlargement is not associated with diabetes: a population-based study. <i>Andrology</i> , 3(5): 933-6.
45360	Chokkalingam AP, Pollak M, Fillmore C-M, Gao Y-T, et al (2001). Insulin-like growth factors and prostate cancer: a population-based case-control study on China. <i>Cancer Epidemiology, Biomarkers & Prevention</i> , Vol 10 pp 421-427.
76206	Chung JH, Yu JH, Sung LH, et al (2012). Effect of prostatitis on lower urinary tract symptoms: retrospective analysis of prostate biopsy tissue. <i>Korean J Urol</i> , 53(2): 109-13. [Abstract]
76151	Chung SD, Lin HC (2011). Increased risk of benign prostatic enlargement among patients with liver cirrhosis: a nationwide population-based study. <i>J Androl</i> , 32(2): 159-64.
7013	Chyou P-H, Nomura AMY, Stemmermann GN, Hankin JH (1993). A prospective study of alcohol, diet and other lifestyle factors in relation to obstructive Uropathy. <i>The Prostate</i> , 22: 253-64.
15637	Colao A, Marzullo P, Ferone D, et al (1998). Prostatic hyperplasia: an unknown feature of acromegaly. <i>Journal of Clinical Endocrinology & Metabolism</i> , 83(3): 775-9.
16602	Colao A, Marzullo P, Lombardi G (1998)[Letter]. Prostatic hyperplasia in patients with acromegaly - authors' response. <i>Journal of Clinical Endocrinology and Metabolism</i> , 83(7) pp 2606-2607.

45076	Collins MM, Meigs JB, Barry MJ, Corkery EW, Giovannucci E, Kawachi I (2002). Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. <i>J Urol</i> , 167(3) pp 1363-1366.
11204	Conn HO (1989). Metoprolol-induced hepatitis: is the rate of oxidation related to drug-induced hepatotoxicity? <i>Hepatology</i> , 9(1): 163-8.
76285	Corona G, Monami M, Rastrelli G, et al (2010). Type 2 diabetes mellitus and testosterone: a meta-analysis study. <i>Int J Androl</i> , 34: 528-40.
76996	Corona G, Vignozzi L, Rastrelli G, et al (2014). Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. <i>Int J Endocrinol</i> , 2014(Article ID 329456): 14 pages.
45148	Corradi G, Bucsek M, Panovics J, Verebelyi A, Kardos M, Kadar A, Frang D (1996). Detection of chlamydia trachomatis in the prostate by in-situ hybridization and by transmission electron microscopy. <i>International Journal of Andrology</i> , 19(2) pp 109-112.
45021	Costabile RA, Steers WD (2006). How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? <i>J Sex Med</i> , Vol 3 pp 676-681.
45168	Crispo A, Talamini R, Gallus S, Negri E, et al (2004). Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. <i>Urology</i> , 64(4) pp 717-722.
76140	Cunningham G, Kadmon D (2015). Patient information: benign prostatic hyperplasia (BPH) (beyond the basics). . Retrieved 16 October 2015, from http://www.uptodate.com.au/contents/benign-prostatic-hyperplasia-bph-beyond-the-basics
76154	Cunningham G, Kadmon D (2015). Epidemiology and pathogenesis of benign prostatic hyperplasia. Retrieved 19 October 2015, from http://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-benign-prostatic-hyperplasia?source=see_link
44908	Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, et al (2002). Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. <i>The Journal of Urology</i> , Vol 168 pp 599-604.
44915	Dal Maso L, Zucchetto A, Tavani A, et al (2006). Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. <i>Int J Cancer</i> , 118(10): 2632-5.
45356	Daniell HW (1993). Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. Vol 149 pp 315-317.
16336	Daniell HW (1993). More stage A prostatic cancers, less surgery for benign hypertrophy in smokers. <i>The Journal of Urology</i> , 149(1-4): 68-72.
11487	de Kretser D (1994). <i>PROS TRENDS</i> . ., (2): 1-4.
76227	De Nunzio C, Albisinni S, Gacci M, et al (2013). The role of inflammation in the progression of benign prostatic hyperplasia. <i>Current Bladder Dysfunction</i> , 8(2): 142-9.
11441	de Voogt HJ (1991). Biology of the prostate. <i>Progress in Clinical & Biological Research</i> , 370: 207-12.
45165	Eaton CL (2003). Aetiology and pathogenesis of benign prostatic hyperplasia. <i>Current Opinion in Urology</i> , Vol 13 pp 7-10.
76283	Egan K, Burnett A, McVary K (2015). The co-occurring syndrome-coexisting erectile dysfunction and benign prostatic hyperplasia and their clinical correlates in aging men: results from the national health and nutrition examination survey. <i>Urology</i> , : Retrieved 29 October 2015, from http://dx.doi.org/10.1016/j.urology.2015.04.054
45385	Enger SM, Van Den Eeden SK, Sternfeld B, Loo RK, Quesenberry CP Jr, Rowell S, Sadler MC, et al (2006). California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. <i>BMC Public Health</i> , Vol 6 pp 172.

46493	Engstrom G, Henningsohns L, Steineck G, Leppert J (2005). Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. <i>BJU Int</i> , 95:810-5.
76205	Espinosa G (2013). Nutrition and benign prostatic hyperplasia. <i>Current Opinion in Urology</i> , 23(1): 38-41.
76280	Fowke JH, Phillips S, Koyama T, et al (2013). Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. <i>BJU Int</i> , 111(1): 122-8.
44918	Fritschi L, Glass DC, Tabrizi JS, Leavy JE, Ambrosini GL (2007). Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case-control study in Western Australia. <i>Occup Environ Med</i> , 64: 60-5.
46494	Fritschi L, Tabrizi J, Leavy J, Ambrosini G, Timperio A (2007). Risk factors for surgically treated benign prostatic hyperplasia in Western Australia. <i>Public Health</i> , 121:781-9.
46308	Fritschi L, Tabrizi J, Leavy J, Ambrosini G, Timperio A (2007). Risk factors for surgically treated benign prostatic hyperplasia in Western Australia. <i>Public Health</i> , 121:781-9.
76392	Gacci M, Corona G, Vignozzi L, et al (2015). Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. <i>BJU Int</i> , 115(1): 24-31.
15402	Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ (1995). A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. <i>The prostate</i> , Vol 26 pp 40-49.
15547	Gao S-J, & Moore PS (1996). Molecular approaches to the identification of unculturable infectious agents. <i>Emerging Infectious Diseases</i> , Vol 2 (3) pp 159-167.
11491	Gardiner RA (1995). Prospectives. <i>Contemporary Issues in Managing Prostatic Disease</i> , 5: 1- 2.
44909	Gass R (2002). Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. <i>BJU International</i> , Vol 90 pp 649-654.
11258	Geldof AA, Engel C, Rao BR (1992). Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia. <i>Urological Research</i> , 20: 139-44.
11257	Geller J (1991). Benign prostatic hyperplasia: Pathogenesis and medical therapy. <i>The American Geriatrics Society</i> , 39: 1208-16.
11196	Giovannucci E, Rimm EB, Chute CG, Kawachi I, et al (1994). Obesity and benign prostatic hyperplasia. <i>American Journal of Epidemiology</i> , 140(11): 989-1002.
44921	Girman CJ (1998). Population-based studies of the epidemiology of benign prostatic hyperplasia. <i>Br J Urol</i> , 82(Suppl 1) pp 34-43.
11190	Gleason PE, Jones JA, Regan JS, Salvias DB, et al (1993). Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia. <i>The Journal Of Urology</i> , 149: 1586-92.
7014	Glynn RJ, Champion EW, Bouchard GR, Silbert JE (1985). The development of benign prostatic hyperplasia among volunteers in the normative aging study. <i>Am J Epidemiol</i> , 121(1): 78-90.
7015	Gordon GG, Altman K, Southren AL, Rubin E, Lieber CS (1976). Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. <i>NEJM</i> , 295(15): 793-97.
15523	Gray A, Feldman HA, McKinlay JB and Longcope C (1991). Age, Disease, and Changing Sex Hormone Levels in Middle-Aged men: Results of the Massachusetts Male Aging Study. <i>Journal of Clinical Endocrinology & Metabolism</i> 73 (5) pp1016-25.

3284	Greenwald P, Kirmss V, Polan AK, Dick VS (1974). Cancer of the prostate among men with benign prostatic hyperplasia. <i>J Nat Can Institute</i> , 53(2): 335-40.
74374	Greim H, Snyder R (2008). Introduction to the discipline of toxicology. <i>Toxicology and Risk Assessment: A comprehensive introduction</i> , 1. John Wiley & Sons.
15549	Griffiths K & Eaton CL (1994). The pathogenesis of BPH: role of hormones. <i>Progress in Clinical & Biological Research</i> , Vol 386 pp33-41.
11429	Griffiths K, Eaton CL, Harper ME, Peeling B, et al (1991). Steroid hormones and the pathogenesis of benign prostatic hyperplasia. <i>European Urology</i> , 20(suppl 2): 68-77.
15398	Gu F (1997). Changes in the prevalence of benign prostatic hyperplasia in China. <i>Chinese Medical Journal</i> , 110(3) pp 163-166.
11236	Guess HA (1992). Benign prostatic hyperplasia: antecedents and natural history. <i>Epidemiologic Reviews</i> , 14: 131-53.
28919	Guess HA (2001). Benign prostatic hyperplasia and prostate cancer. <i>Epidemiologic Reviews</i> , 23(1): 152-8.
72440	Guidotti TL (2014). Health risks and occupation as a firefighter. <i>Medical Advisory Services</i> , . Department of Veterans' Affairs, Commonwealth of Australia.
45030	Gupta A, Gupta S, Pavuk M, Roehrborn CG (2006). Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. <i>Urology</i> , 68(6) pp 1198-1205.
45026	Gupta A, Ketchum N, Roehrborn CG, et al (2006). Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force Veterans. <i>Environmental Health Perspectives</i> , 114(111): 1649-54.
45206	Gupta A, Schecter A, Aragaki CC, Roehrborn CG (2006). Dioxin exposure and benign prostatic hyperplasia. <i>J Occup Environ Med</i> , Vol 48 pp 708-714.
45081	Haidinger G, Madersbacher S, Waldhoer T, Lunglmayr G, Vutuc C (1999). The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. <i>Eur J Epidemiol</i> , 15(8) pp 717-722.
45083	Hammarsten J, Hogstedt B (2001). Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. <i>Eur Urol</i> , 39(2) pp 151-158.
45080	Hammarsten J, Hogstedt B (1999). Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. <i>Blood Pressure</i> , 8(1) pp 29-36.
45334	Hart LE (1999). Physical activity and benign prostatic hyperplasia. <i>Clin J Sport Med</i> , 9(2) pp 106.
46858	Hassler E, Krakau I, Haggarth L, Norlen L, Ekman P (2001). Questioning questions about symptoms of benign prostatic hyperplasia. <i>Family Practice</i> , 18(3) pp 328-332.
76282	He Q, Wang H, Yue Z (2014). Waist circumference and risk of lower urinary tract symptoms: a meta-analysis. <i>Aging Male</i> , 17(4): 223-9.
46869	Heber D (2002). Prostate enlargement: the canary in the coal mine? <i>Am J Clin Nutr</i> , 75(4) pp 605-606.
15493	Hennenfert B (1997). Prostatitis and Benign Prostatic Hyperplasia: Emerging Infectious Diseases? <i>Emerging Infectious Diseases</i> , 3(1) pp 77-78.
45198	Hochreiter WW, Nadler RB, Koch AE, Campbell PL, et al (2000). Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. <i>Urology</i> , Vol 56 pp 1025-1029.
45028	Hong J, Kwon S, Woon H, Lee H, et al (2006). Risk factors for benign prostatic hyperplasia in South Korean men. <i>Urologia Internationalis</i> , Vol 76 pp 11-19.

76998	Howe O, O'Malley K, Lavin M, et al (2005). Cell death mechanisms associated with G2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia. <i>Rad Res</i> , 164(5): 627-34.
46188	IARC Working Group (2006). Inorganic and organic lead compounds. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 87. World Health Organization.
45196	Irani J, Goujon; Nickel JC (2000). [Letters] Asymptomatic inflammation and/or infection in benign prostatic inflammation. <i>BJU International</i> , Vol 85 pp 1155-1157.
11430	Isaacs JT (1994). Etiology of benign prostatic hyperplasia. <i>European Urology</i> , 25(suppl 1): 6-9.
11431	Isaacs JT, Coffey DS (1989). Etiology and disease process of benign prostatic hyperplasia. <i>The Prostate</i> , (Suppl 2): 33-50.
46862	Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, et al (2003). Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. <i>Am J Epidemiol</i> , 157(10) pp 906-914.
44910	Joseph MA, Wei JT, Harlow SD, Cooney KA, et al (2002). Relationship of serum sex-steroid hormones and prostate volume in African American men. <i>The Prostate</i> , Vol 53 pp 322-329.
44912	Kang D, Andriole GL, Van De Vooren RC, et al (2004). Risk behaviours and benign prostatic hyperplasia. <i>BJU International</i> , 93(9): 1241-5.
66022	Kasper JS, Giovannucci E (2006). A meta-analysis of diabetes mellitus and the risk of prostate cancer. <i>Cancer Epidemiol Biomarkers Prev</i> , 15: 2056-62.
45020	Kasturi S, Russell S, McVary KT (2006). Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Current Urology Reports</i> , Vol 7 pp 288-292.
32506	Kaufman JM (2003). The effect of androgen supplementation therapy on the prostate. <i>Aging Male</i> , 6(3): 166-74.
46495	Kellogg Parsons J (2007). Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. <i>J Urol</i> , 178:395-401.
11488	Kirby R S (). Prospectives contemporary issues in Managing Prostatic Disease. , 1(1): 1-5.
11492	Kirby R S (). PROSPECTIVES Contemporary Issues in Managing Prostatic Disease. ., 5(5): 1, 7- 8.
11489	Kirby R S (1995). Prospectives. Contemporary issues in Managing Prostatic Disease, 1(7): 1-3, 6-8.
11490	Kirby R S (1995). Prospectives. Contemporary Issues in Managing Prostatic Disease, 1(2): 1-6.
77104	Kirby R, McConnell JD, Fitzpatrick JM, et al (2004). Textbook of benign prostatic hyperplasia. CRC Press, 2nd Edition,: 170. .
46861	Klein BEK, Klein R, Lee KE, Bruskewitz RC (1999). Correlates of urinary symptom scores in men. <i>Am J Public Health</i> , 89(11) pp 1745-1748.
11201	Kliwer EV (1996). Benign prostatic hyperplasia morbidity and mortality among immigrants in Australia and Canada. <i>The Prostate</i> , 28: 211-8.
45077	Koskimaki J, Hakama M, Huhtala H, Tammela TLJ (2000). Association of dietary elements and lower urinary tract symptoms. <i>Scand J Urol Nephrol</i> , 34(1) pp 46-50.
13906	Koskimaki J, Hakama M, Huhtala H, Tammela TLJ (1998). Association of smoking with lower urinary tract symptoms. <i>The Journal of Urology</i> , 159: 1580-2.
45163	Krieger JN (2004). Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. <i>Minerva Urol Nefrol</i> , Vol 56 pp 99-107.
76155	Kristal A, Arnold K, Schenk J, et al (2008). Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>Am J Epidemiol</i> , 167(8): 925-34.

44920	Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, et al (2007). Race/ethnicity, obesity, health related behaviours and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>J Urol</i> , Vol 177 pp 1395-1400.
76999	Kumar R, Verma V, Sarswat A, et al (2012). Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms- action of two new agents. <i>Invest New Drugs</i> , 30(2): 582-93.
77000	Kumar S, Yadav RN, Gupta P, et al (2015). Prostatic hyperplasia in acromegaly, a myth or reality: a case-control study. <i>Eur J Endocrinol</i> , 172(2): 97-106.
46870	Kumar V, Abbas AK, Fausto N (2005). Robbins and Cotran Pathologic Basis of Disease. Seventh Edition. Unit II Diseases of Organ Systems, Benign Enlargement, pp 1048-1050. Philadelphia : Elsevier Saunders.
76178	Kumar V, Banerjee B, Datta S, et al (2014). Association of CYP1A1, CYP1B1 and CYP17 gene polymorphisms and organochlorine pesticides with benign prostate hyperplasia. <i>Chemosphere</i> , 108: 40-5.
15393	Kupeli B, Soygur T, Aydos K, Oziler E & Kupeli S (1997). The role of cigarette smoking in prostatic enlargement. <i>British Journal of Urology</i> , Vol 80 pp 201-4.
77001	Kupelian V, Araujo AB, Wittert GA, et al (2015). Association of moderate to severe lower urinary tract symptoms with incident type 2 diabetes and heart disease. <i>J Urol</i> , 193(2): 581-6.
28952	Lacey JV Jr, Deng J, Dosemeci M, Gao YT, Mostofi FK, et al (2001). Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. <i>International Journal of Epidemiology</i> , 30: 341-9.
45073	Lagiou P, Wu J, Trichopoulos A, Hsieh C-C, Adami H-O, Trichopoulos D (1999). Diet and benign prostatic hyperplasia: a study in Greece. <i>Urology</i> , 54(2) pp 284-290.
11202	Lee C, Koslowski JM and Grayhack JT (1997). Intrinsic and extrinsic factors controlling benign prostatic growth. <i>The Prostate</i> , 31: 131-8.
11198	Lee C, Koslowski JM, Grayhack JT (1995). Etiology of benign prostatic hyperplasia. <i>Urologic Clinics of North America</i> , 22(2): 237-46.
11205	Lee E, Park M-S, Shin C, Lee H, et al (1997). A high-risk group for prostatism: a population-based epidemiological study in Korea. <i>British Journal of Urology</i> , 79: 736-41.
46867	Lee S, Min HG, Choi SH, Kim YJ, Oh SW, Kim YJ, Park Y, Kim SS (2006). Central obesity as a risk factor for prostatic hyperplasia. <i>Obesity</i> , 14(1) pp 172-179.
14596	Lees RE, Steele R, Wardle D (1985). Arsenic, syphilis and cancer of the prostate. <i>J Epidemiol Comm Health</i> , 39(3): 227-30.
46914	Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C (2006). Serum lipid levels in benign prostatic hyperplasia. <i>World J Urol</i> , 24: 210-213.
15400	Levine AC, Kirschenbaum A, Gacrilove JL (1997). The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. <i>The Mount Sinai Journal of Medicine</i> , 64(1): pp.
76177	Lewis-Mikhael A, Olmedo-Requena R, Martinez-Ruiz V, et al (2015). Organochlorine pesticides and prostate cancer, is there an association? A meta-analysis of epidemiological evidence. <i>Cancer Causes Control</i> , 26(10): 1375-92.
77002	Ma Y, Zhang WL (2010). Benign prostate hyperplasia with chronic prostatitis: an update. <i>Zhonghua Nan Ke Xue</i> , 16(7): 646-50. [Abstract]
46868	Marcelli M, Cunningham GR (1999). Hormonal signaling in prostatic hyperplasia and neoplasia. <i>J Clin Endocrinol Metab</i> , 84(10) pp 3463-3468.
45070	Matzkin H, Cytron S, Simon D (1996). Is there an association between cigarette smoking and gland size in benign prostatic hyperplasia? <i>The Prostate</i> , 29(1) pp 42-45.

11189	Matzkin H, Soloway MS (1993). Cigarette smoking: a review of possible associations with benign prostatic hyperplasia and prostate cancer. <i>The Prostate</i> , 22: 277-90.
46856	McGraw-Hill's Access Medicine. Harrison's Internal Medicine. Chapter 81. Hyperplastic and malignant diseases of the prostate: introduction.
45029	McVary KT (2005). Erectile dysfunction and lower urinary tract symptoms secondary to BPH. <i>European Urology</i> , Vol 47 pp 838-845.
76525	McVary KT, Roehrborn CG, Avins AL, et al (2011). Update on AUA guideline on the management of benign prostatic hyperplasia. <i>Journal of Urology</i> , 185(5): 1793-1803.
77003	Mehta V, Vezina CM (2011). Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia. <i>Differentiation</i> , 82(4-5): 211-9.
45075	Meigs JB, Mohr B, Barry MJ, et al (2001). Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. <i>J Clin Epidemiol</i> , 54(9): 935-44.
45162	Michel M, Heeman U, Schumacher H, et al (2004). Association of hypertension with symptoms of benign prostatic hyperplasia. <i>The Journal of Urology</i> , 172(4): 1390-3.
45069	Michel MC, Mehlburger L, Schumacher H, et al (2000). Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. <i>J Urol</i> , 163(6): 1725-9.
45147	Mohanty NK, Jolly BB (1996). Prevalence of bacterial prostatitis in benign prostatic hyperplasia. <i>Indian J Pathol Microbiol</i> , 39(2) pp 111-114.
11194	Montie JE, Pienta KJ (1994). Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. <i>Urology</i> , 43(6): 892-9.
74375	Moon DG, Lee KC, Kim YW, et al (2004). Effect of TCDD on corpus cavernosum histology and smooth muscle physiology. <i>International Journal of Impotence Research</i> , 16: 224 - 30.
11195	Moon TD, Brannan W, Stone NN, Ercole C, et al (1994). Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. <i>The Journal of Urology</i> , 152: 1498-500.
45205	Morales A (2004). Testosterone treatment for the aging man: the controversy. <i>Current Urology Reports</i> , Vol 5 pp 472-477.
76202	Moreira D, Nickel J, Gerber L, et al (2015). Smoking is associated with acute and chronic prostatic inflammation: results from the REDUCE study. <i>Cancer Prev Res</i> , 8(4): 312-7.
45200	Morrison AS (1978). Prostatic hypertrophy in greater Boston. <i>J Chron Dis</i> , Vol 31 pp 357-362.
7016	Morrison AS (1992). Risk factors for surgery for prostatic hypertrophy. <i>American Journal of Epidemiology</i> , 135(9): 974-80.
11184	Morrison AS (1992). Risk factors for surgery for prostatic hypertrophy. <i>American Journal of Epidemiology</i> , 135(9): 974-80.
44911	Moyad MA (2003). Lifestyle changes to prevent BPH: heart healthy = prostate healthy. <i>Urologic Nursing</i> , 23(6) pp 439-441.
76136	Nandeesh H (2008). Benign prostatic hyperplasia: dietary and metabolic risk factors. <i>Int Urol Nephrol</i> , 40: 649-56.
45149	Nandeesh H, Koner BC, Dorairajan LN, Sen SK (2006). Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. <i>Clinica Chimica Acta</i> , 370(1-2) pp 89-93.
11199	Napalkov P, Maisonneuve P, Boyle P (1995). Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. <i>Urology</i> , 46: 41-6.
46871	National Research Council (2006). Health risks from exposure to low levels of ionizing radiation. Beir VII Phase 2, . The National Academies Press, Washington D.C.

45171	Neuhouser ML, Kristal AR, Penson DF (2004). Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. <i>Urology</i> , 64(2) pp 201-211.
76137	Nicholson T, Moses M, Uchtmann K, et al (2015). Estrogen receptor-alpha is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. <i>J Urol</i> , 193(2): 722-9.
76208	Nicholson TM, Ricke WA (2011). Androgens and estrogens in benign prostatic hyperplasia: past, present and future. <i>Differentiation</i> , 82(4-5): 184-199.
45164	Nickel J (2006). The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. <i>Current Opinion in Urology</i> , Vol 16 pp 5-10.
45197	Nickel JC, Downey J, Young I, Boag S (1999). Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. <i>BJU International</i> , Vol 84 pp 976-981.
44914	Nickel JC, Elhilali M, Vallancien G (2005). Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. <i>BJU International</i> , Vol 95 pp 571-574.
28736	NRCET (National Research Centre for Environmental Toxicology (ENTOX) (2002). Examination of the potential exposure of Royal Australian Navy (RAN) personnel to polychlorinated dibenzodioxins and polychlorinated dibenzofurans via drinking water. A Report to the Dept Of Veteran Affairs, Australia, . .
45249	Nukui M (1997). Epidemiologic study on diet, smoking and alcohol drinking in the relationship to prostatic weight. <i>The Japanese Journal of Urology</i> , Vol 88 pp 950-956.
45391	Ochiai A, Fritsche HA, Babaian RJ (2005). Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. <i>Urology</i> , Vol 66 pp 819-823.
15396	Ohno Y, Yoshida O, Oishi K, Okada K, Yamabe H, & Schroeder FH. (1988). Dietary b-Carotene and cancer of the prostate: a case-control study in Kyoto, Japan. <i>Cancer Research</i> , Vol 48 pp 1331-6.
31615	Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH, Boyle P (1990). A case-control study of prostatic cancer in Kyoto, Japan: sexual risk factors. <i>The Prostate</i> , 17: 269-79.
30703	Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH (1998). A case-control study of prostatic cancer with reference to dietary habits. <i>The Prostate</i> , 12: 179-181 & 184-190.
15395	O'Leary MP (1995). Epidemiology of benign prostatic hyperplasia. <i>British Journal of Urology</i> , Vol 76 Suppl 1 pp 1-3.
45914	Overland GB, Vatten L, Rhodes T, DeMuro C, et al (2001). Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. <i>Eur Urol</i> , Vol 39 pp 36-41.
70194	Ozasa K, Shumizu Y, Suyama A, et al (2012). Studies of the mortality of atomic bomb survivors, Report 14, 1950-2003: An overview of cancer and noncancer diseases. <i>Radiat Res</i> , 177(3): 229-43.
77004	Paolone DR (2010). Benign prostatic hyperplasia. <i>Clin Geriatr Med</i> , 26(2): 223-39.
76139	Parnham A, Haq A (2013). Benign prostatic hyperplasia. <i>Journal of Clinical Urology</i> , 6(1): 24-31.
76135	Parsons J (2011). Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. <i>Current opinion in Urology</i> , 21(1): 1-4.
76141	Parsons J, Im R (2009). Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. <i>The Journal of Urology</i> , 182(4): 1463-8.

76144	Parsons J, Kashefi C (2008). Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. <i>Eur Urol</i> , 53(6): 1228-35.
76203	Parsons J, Messer K, White M, et al (2011). Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the osteoporotic fractures in men study. <i>Eur Urol</i> , 60(6): 1173-80.
76133	Parsons J, Sarma A, McVary K, et al (2013). Obesity and benign prostatic hyperplasia: clinical connections emerging etiological paradigms and future directions. <i>The Journal of Urology</i> , 189(1): s102-6.
76152	Parsons JK (2010). Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. <i>Curr Bladder Dysfunct Rep</i> , 5: 212-8.
44916	Parsons JK, Carter HB, Partin AW, Windham BG, et al (2006). Metabolic factors associated with benign prostatic hyperplasia. <i>J Clin Endocrinol Metab</i> , Vol 91 pp 2562-2568.
45203	Partin AW (2000). Etiology of benign prostatic hyperplasia. Lepor H, (ed). <i>Prostatic diseases</i> . Philadelphia, PA: Saunders, pp 95-105.
76284	Partin AW, Oesterling JE, Epstein JI (1991). Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. <i>J Urol</i> , 145(2): 405-9. [Abstract]
45355	Pasquali R, Casimirri F, Cantobelli S, Melchionda N, et al (1991). Effect of obesity and body fat distribution on sex hormones and insulin in men. <i>Metabolism</i> , 40(1) pp 101-104.
76134	Patel N, Parsons J (2014). Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. <i>Indian J Urol</i> , 30(2): 170-6.
46857	Petersen LA (1998). Recent advances: general medicine. <i>BMJ</i> , 317(7161) pp 792-795.
15394	Platz EA, Kawachi I, Rimm EB, Colditz GA, et al (1998). Physical activity and benign prostatic hyperplasia. <i>Arch Intern Med</i> , Vol 158 pp 2349-2356.
46859	Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Giovannucci E (1999). Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. <i>Am J Epidemiol</i> , 149(2) pp 106-115.
11191	Porta M, Fernandez E, Alonso J, Anto JM (1994). Re: risk factors for benign prostatic hypertrophy. <i>American Journal of Epidemiology</i> , 139(1): 114-5.
44922	Potter SR, Partin AW (1999). Prostatitis syndromes and benign prostatic hyperplasia. <i>Seminars in Roentgenology</i> , 34(4) pp 256-268.
45248	Prezioso D, Catuogno C, Galassi P, D'Andrea G, et al (2001). Life-style in patients with LUTS suggestive of BPH. <i>European Urology</i> , 40(S1) pp 9-12.
76179	Ragin C, Davis-Reyes B, Tadesse H, et al (2013). Farming, reported pesticide use, and prostate cancer. <i>Am J Mens Health</i> , 7(2): 102-9.
76175	Raheem O, Parsons J (2014). Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. <i>Curr Opin Urol</i> , 24(1): 10-4.
45022	Ranjan P, Dalela D, Sankhwar SN (2006). Diet and benign prostatic hyperplasia: implications for prevention. <i>Urology</i> , 68(3) pp 470-476.
32521	Rhoden EL, Morgentaler A (2004). Risks of testosterone-replacement therapy and recommendations for monitoring. <i>NEJM</i> , 350(5): 482-92.
76176	Robert G (2010). Inflammation and benign prostatic hyperplasia: cause or consequence? <i>Prog Urol</i> , 20(6): 402-7. [Abstract]
46860	Roberts Ro, Jacobsen SJ (1999). [Letter] Re: "alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia". <i>Am J Epidemiol</i> , 150(3) pp 321.
11193	Roberts RO, Jacobsen SJ, Rhodes T, Guess HA, et al (1994). Cigarette smoking and prostatism: a biphasic association? <i>Urology</i> , 43(6): 797-9.
15399	Roberts RO, Tsukamoto T, Kumamoto Y, Rodes T, Masumori N, Miyake H, Girman CJ, Jacobsen SJ, & Lieber MM. (1997). Association between cigarette smoking and prostatism in a Japanese Community. <i>The Prostate</i> , Vol 30 pp 154-159.

76142	Roehrborn CG (2008). Pathology of benign prostatic hyperplasia. <i>International Journal of Impotence Research</i> , 20: s11-18.
77105	Roehrborn CG, Cassab A, Glina S, et al (2015). Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. <i>Int J Urol</i> , 22(6): 582-7.
47020	Roehrborn CG, Marberger M, Wolford ET, Wilson TH (2006). Relationships between alcohol use and measures of LUTS/BPH severity: baseline data from dutasteride studies involving a total of 18,914 subjects. Obtained from http://www.urotoday.com/index2.php?option=com_content&task=view&id=20242&I
15548	Roehrborn CG. (1994). Some socio-economic issues surrounding prostatectomy: the US experience. <i>Progress in Clinical & Biological Research</i> , Vol 386 pp 419-25.
45392	Rohrmann S, Crespo CJ, Weber JR, et al (2005). Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health and Nutrition Examination Survey. <i>BJU</i> , 96: 77-82.
45393	Rohrmann S, Fallin MD, Page WF, Reed T, et al (2006). Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. <i>Epidemiology</i> , Vol 17 pp 419-427.
44919	Rohrmann S, Giovannucci E, Willett WC, Platz EA (2007). Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. <i>Am J Clin Nutr</i> , Vol 85 pp 523-529.
45195	Rohrmann S, Platz EA, Smit E, Giovannucci E (2004). [Letter] Re: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. <i>Journal of Urology</i> , 172(2) pp 779.
45390	Rohrmann S, Smit E, Giovannucci E, Platz EA (2005). Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). <i>International Journal of Obesity</i> , Vol 29 pp 310-316.
45358	Rohrmann S, Smit E, Giovannucci E, Platz EA (2004). Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. <i>American Journal of Epidemiology</i> , 159(4) pp 390-397.
7210	Ross RK, Bernstein L, Panganini-Hill A, Henderson BE (1990). Effects of cigarette smoking on 'hormone-related' diseases in a Southern California retirement community. <i>Smoking and Hormone-Related Disorders</i> , Oxford University Press, Oxford.
76358	Saad F, Haider A, Yassin A, et al (2014). 156 hypogonadal men with obesity and type 2 diabetes achieve weight loss and improved glycaemic control upon treatment with testosterone undecanoate up to 6 years: a subgroup analysis from two observational registry studies. <i>Journal of Mens Health</i> , 11(1): 140.
45386	Sandfeldt L, Hahn RG (2003). Cardiovascular risk factors correlate with prostate size in men with bladder outlet obstruction. <i>BJU International</i> , Vol 92 pp 64-68.
11192	Santti R, Newbold RR, Makela S, Pylkkanen L et al (1994). Developmental estrogenization and prostatic neoplasia. <i>The Prostate</i> , 24: 67-78.
76210	Sarma A, Parsons J, McVary K, et al (2009). Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms- what do we know? <i>The Journal of Urology</i> , 182(6): s32-s37.
45357	Sarma AV, Jaffee CA, Schottenfeld D, Dunn R, et al (2002). Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among black men. <i>Urology</i> , Vol 59 pp 362-367.

45705	Schechter A, Birnbaum L, Ryan JJ, et al (2006). Dioxins: an overview. <i>Environmental Research</i> , 101: 419-28.
45170	Schultheiss D, Machtens S, Jonas U (2004). Testosterone therapy in the ageing male: what about the prostate? <i>Andrologia</i> , Vol 36 pp 355-365.
11259	Scolnik MD, Servadio C, Abramovici A (1994). Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. <i>Journal of Andrology</i> , 15: 287-97.
76204	Sea J, Poon K, McVary K (2009). Review of exercise and the risk of benign prostatic hyperplasia. <i>Physician and Sportsmedicine</i> , 37(4): 75-83.
45201	Seftel A (2005). Male and female sexual function and dysfunction; andrology. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. <i>The Journal of Urology</i> , Vol 174 pp 1939.
46915	Seim A, Hoyo C, Ostbye T, Vatten L (2005). The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT Study. <i>BJU International</i> , 96: 88-92.
7018	Seitter WR, Barrett-Connor E (1992). Cigarette smoking, obesity and benign prostatic hypertrophy: A prospective population-based study. <i>Am J Epidemiol</i> , 135(5): 500-3.
11188	Seitter WR, Barrett-Connor E (1992). Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study. <i>American Journal of Epidemiology</i> , 135(5): 500-3.
45024	Shakya G, Malla S, Shakya KN (2003). Salient and co-morbid features in benign prostatic hyperplasia: a histopathological study of the prostate. <i>Kathmandu University Medical Journal</i> , 1(2): 104-9.
29371	Siddiqui MK, Srivastava S, Mehrotra PK (2002). Environmental exposure to lead as a risk for prostate cancer. <i>Biomedical & Environmental Sciences</i> , 15(4): 298-305.
45199	Sidney S, Lydick EG, Quesenberry C, Guess HA, et al (1991). Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. <i>Supplement to Urology</i> , 38(1) pp 13-19.
45074	Signorello LB, Tzonou A, Lagiou P, Samoli E, Zavitsanos X, Trichopoulos D (1999). The epidemiology of benign prostatic hyperplasia: a study in Greece. <i>BJU International</i> , 84(3) pp 286-291.
45071	Simpson RJ, Fisher W, Lee AJ, Russell EBAW, Garraway M (1996). Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. <i>Br J Urol</i> , 77(2) pp 186-191.
45167	Skolarikos A, Thorpe AC, Neal DE (2004). Lower urinary tract symptoms and benign prostatic hyperplasia. <i>Minerva Urol Nefrol</i> , 56(2) pp 109-122.
76191	Smith D, Weber M, Soga K, et al (2014). Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,436 middle-aged and older Australian men: population-based study. <i>PLoS One</i> , 9(10): e109278.
11405	Soygur T, Kupeli B, Aydos K, Kupeli S, et al (1996). Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. <i>International Urology and Nephrology</i> , 28(1): 55-9.
76279	Stamatiou K, Copanitsanou P (2012). Is there any association between obesity and benign prostatic hyperplasia? <i>Int J of Urol Nurs</i> , 6(1): 11-6.
29250	Steele R, Lees REM, Kraus AS, Rao C (1971). Sexual factors in the epidemiology of cancer of the prostate. <i>Journal of Chronic Diseases</i> , 24: 29-37.
46865	Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA (2005). Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. <i>Am J Epidemiol</i> , 162(9) pp 898-906.

46864	Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E (2002). Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. <i>Am J Clin Nutr</i> , 75(4) pp 689-697.
45166	Tan RS, Salazar (2004). Risks of testosterone replacement therapy in aging men. <i>Expert Opin. Drug Saf.</i> , 3(6) pp 599-606.
45025	Thorpe A, Neal D (2003). Benign prostatic hyperplasia. <i>Lancet</i> , Vol 361 pp 1359-1367. Erratum: (2003) <i>The Lancet</i> , Vol 362 pp 496.
45079	Toth M, Patton DL, Campbell LA, Carretta EI, Mouradian J, et al (2000). Detection of chlamydial antigenic material in ovarian, prostatic, ectopic pregnancy and semen samples of culture-negative subjects. <i>AJRI</i> , 43(4) pp 218-222.
76209	Tseng C (2013). Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the national health insurance in Taiwan. <i>BMC Cancer</i> , 13: 7.
45202	Tubaro A, La Vecchia C (2005). The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. <i>Journal of Urology</i> , Vol 173 pp 2058.
46866	Ullrich PM, Lutgendorf SK, Leserman J, Turesky DG, Kreder KJ (2005). Stress, hostility, and disease parameters of benign prostatic hyperplasia. <i>Psychosomatic Medicine</i> , 67(3) pp 476-482.
46734	Usai E, Scarpa RM, De Lisa A, Porru D (1995). Benign prostatic hyperplasia: associated pathology. <i>J Urol (Paris)</i> , 101(1) pp 53-54.
76288	Vikram A, Jena G, Ramarao P (2010). Insulin-resistance and benign prostatic hyperplasia: the connection. <i>Eur J Pharmacol</i> , 641(2-3): 75-81.
76289	Vikram A, Jena G, Ramarao P (2010). Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostatic hyperplasia. <i>The Prostate</i> , 70(1): 79-89.
15550	Villers A (1994). Anatomy of the prostate: insight into benign prostatic hyperplasia anatomy and pathogenesis. <i>Progress in Clinical & Biological Research</i> , Vol 386 pp 21-30.
76287	Wallner L, Hollingsworth J, Dunn R, et al (2013). Hyperglycemia, hyperinsulinemia, insulin resistance and the risk of BPH/LUTS severity and progression over time in community dwelling black men: the flint men's health study. <i>Urology</i> , 84(4): 881-6.
11203	Walsh PC (1988). This month in investigative urology: the role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia. <i>The Journal of Urology</i> , 139: 826.
76281	Wang S, Mao Q, Lin Y (2012). Body mass index and risk of BPH: a meta-analysis. <i>Prostate Cancer & Prostatic Diseases</i> , 15: 265-72.
76138	Wang W, Guo Y, Zhang D, et al (2015). The prevalence of benign prostatic hyperplasia in mainland china: evidence from epidemiological surveys. <i>Scientific Reports</i> , 5(article13546): .
11197	Wemyss-Holden SA, Hamdy FC, Hastie KJ (1994). Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction - is there a relationship? <i>British Journal of Urology</i> , 74: 476-8.
15401	Wideroff L, Schottenfeld D, Carey TE, Beals T, Fu G, Sakr W, Sarkar F, Schork A, Grossman HB, & Shaw MW. (1996). Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. <i>The Prostate</i> , Vol 28 pp 117-123.
76143	Wolin K, Grubb R, Pakpahan R, et al (2015). Physical activity and benign prostatic hyperplasia - related outcomes and nocturia. <i>Med Sci Sports Exer</i> , 47(3): 581-92.
45220	Wong SYS, Hong A, Leung J, Kwok T, et al (2006). Lower urinary tract symptoms and depressive symptoms in elderly men. <i>Journal of Affective Disorders</i> , Vol 96 pp 83-88.

45169	Xie L-P, Bai Y, Zhang X-Z, Sheng Z-Y, et al (2007). Obesity and benign prostatic enlargement: a large observational study in China. <i>Urology</i> , 69(4) pp 680-684.
45359	Zhuang TN, Ly LP, Cumming RG, Handelsman DJ (2005). Growth and development during early manhood as determinants of prostate size in later life. <i>The Journal of Clinical Endocrinology & Metabolism</i> , 90(11) pp 6055-6063.
45204	Zucchetto A, Tavani A, Dal Maso L, Gallus S, et al (2005). History of weight and obesity through life and risk of benign prostatic hyperplasia. <i>International Journal of Obesity</i> , Vol 29 pp 798-803.